Top Management Presentation Financial Results of FY2017 Q3
(April 1 - December 31, 2017)

from the beginning

Top Management Presentation Financial Results of FY2017 Q3 (April 1 - December 31, 2017)

Forward-Looking Statements

Agenda

FY2017 Q3 Financial Results

Overview of FY2017 Q3 Results

Revenue

Operating Profit

Profit Attributable to Owners of the Company

Revenue: Major Business Units (incl. Forex Impact)

Revenue: Major Products in Japan

FY2017 Revised Consolidated Forecast

FY2017 Revised Consolidated Forecast

Edoxaban (Lixiana)

Lixiana : For Maximization of Product Value

R&D Update

DS-8201: Broad and Bold Program

DS-8201: P1 Study Design

DS-8201: Patient Background

DS-8201: P1 Study Part 1+2b Efficacy(1)

DS-8201: P1 Study Part 1+2b Efficacy(2)

DS-8201: P1 Study Part 1+2b Efficacy(3)

DS-8201: CT Imaging of PR

DS-8201: Adverse Events >20% (N=45)

DS-8201: Conclusions at ASCO GI

DS-8201: Rationale of Neratinib Combo

Appendix

R&D Milestone Events

Major R&D Pipeline

Out-licensing Projects

Lixiana: Growth in Japan(1)

Lixiana: Growth in Japan(2)

Lixiana: Growth in Germany and South Korea

Growth of Injectafer

Abbreviations

@

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4